Active • Host: HEK293 cells • AA: 134-285 • Tag: N-terminal human IgG1 Fc • MW: 43.7 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Soluble BLyS/BAFF (human, recombinant)

Item No. 31824

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • B Cell-activating Factor
  • B Lymphocyte Stimulator
  • BAFF
  • CD257
  • Dendritic Cell-derived TNF-like Molecule
  • DTL
  • TALL-1
  • THANK
  • TNF Ligand Superfamily Member 13B
  • TNF- and APOL-related Leukocyte Expressed Ligand 1
  • TNFSF13B
  • TNFSF20
  • ZTNF4
Purity
≥95% as determined by SDS-PAGE
Endotoxin Testing
<1.0 EU/μg, determined by the LAL endotoxin assay
Source
Active recombinant N-terminal human IgG1 Fc-tagged BLyS/BAFF expressed in HEK293 cells
Amino Acids
134-285
MW
43.7 kDa
Formulation (Request formulation change)
Lyophilized from sterile PBS, pH 7.4
UniProt Accession №
Q9Y275-1
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $422

    Add

    1 mg

    $2,738

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    B lymphocyte stimulator (BLyS), also known as B cell-activating factor (BAFF), is a cytokine that belongs to the TNF ligand superfamily and has roles in B cell survival and differentiation.1,2 It is a type II transmembrane protein with an extracellular C-terminal TNF homology domain that is cleaved from the cell surface by a furin protease and corresponds to the soluble form of BLyS, which circulates as a trimer.1,2,3 BLyS is encoded by the TNFSF13B gene in humans, expressed primarily in monocytes, macrophages, dendritic cells, and neutrophils, and can be upregulated by IFN-γ, IL-10, IFN-α, and CD40 ligand. 1,2,4 Binding of BLyS to the B cell receptors TACI, BCMA, and BAFF-R/BR3 inhibits apoptosis in, as well as increases survival and promotes differentiation of, B cells.1,2 Elevated serum levels of BLyS have been found in patients with rheumatoid arthritis, systemic lupus erythematosus (SLE), and primary Sjögren's syndrome.3 Formulations containing a monoclonal antibody against soluble BLyS have been used in the treatment of SLE.5 Cayman's Soluble BLyS/BAFF (human, recombinant) protein can be used for cell-based assay and ELISA applications. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of BLyS/BAFF (amino acids 134-285) fused to human IgG1 Fc at its N-terminus, consists of 389 amino acids and has a calculated molecular weight of 43.7 kDa. As a result of glycosylation, the monomer migrates at approximately 48-55 kDa by SDS-PAGE under reducing conditions.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Nardelli, B., Moore, P.A., Li, Y., et al. B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk. Lymphoma 43(7), 1367-1373 (2002).

    2. Stohl, W. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr. Metab. Immune Disord. Drug Targets 6(4), 351-358 (2006).

    3. Lahiri, A., Pochard, P., Le Pottier, L., et al. The complexity of the BAFF TNF-family members: Implications for autoimmunity. J. Autoimmun. 39(3), 189-198 (2012).

    4. González-Serna, D., Ortiz-Fernández, L., Vargas, S., et al. Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus. Sci. Rep. 8(1), 8195 (2018).

    5. Sanz, I., Yasothan, U., and Kirkpatrick, P. Belimumab. Nat. Rev. 10, 335-336 (2011).